Emphysema can be measured objectively, with CT quantifying low attenuation areas and lung function tests capturing DLCO reductions tied to impaired gas transfer. The condition also shows up in national cost and care gaps. In the United States, COPD cost about $49.9 billion in total, and more than 50% of cases remain undiagnosed or unrecognized by health systems.
Key Takeaways
- In the United States, indirect costs (e.g., lost productivity) from COPD are estimated at $2.2 billion annually
- More than 50% of COPD cases are undiagnosed or not recognized by health systems (diagnostic gap estimate in review literature)
- A 2013 study estimated total economic burden of COPD in the US at $49 billion
- A 10-year smoking cessation reduces the risk of COPD death by 50%
- Alpha-1 antitrypsin deficiency is responsible for 1–3% of COPD cases
- Up to 20% of people with COPD report that they have never smoked (proportion of COPD cases not attributed to smoking)
- In emphysema CT findings, low attenuation areas are used as a quantitative imaging marker of emphysema severity
- In a lung function measure, emphysema severity can be quantified by diffusing capacity (DLCO) reduction reflecting impaired gas transfer
- In the Global Burden of Disease study, COPD ranked among the top 5 causes of death and disability worldwide in recent decades (ranked 3rd overall in 2019 for mortality and 7th for disability-adjusted life years)
- The global COPD market was estimated at $XX in 2023 (pharmaceutical + related therapies) (industry estimate)
- The number of COPD-focused clinical trials has increased in recent years according to ClinicalTrials.gov counts (annual updates)
- In 2019, COPD was the 3rd leading cause of death worldwide (including emphysema as a COPD phenotype) in the Global Burden of Disease results
- In 2019, COPD ranked 7th for disability-adjusted life years (DALYs) worldwide, reflecting the total disease burden that includes emphysema as a COPD subtype, per Global Burden of Disease
- In 2019, worldwide COPD prevalence was estimated at about 212 million people, which includes emphysema as a phenotype within COPD
- Starting from age 40, the prevalence of chronic bronchitis and emphysema increases with age; a large population-based analysis reported emphysema prevalence rising substantially across adult age bands (age-stratified prevalence study)
Emphysema affects millions worldwide, costs billions, and improved care like rehab, smoking cessation, and imaging helps reduce risk.
Related reading
01 · Category
Treatment & Outcomes8 stats
01
In the United States, indirect costs (e.g., lost productivity) from COPD are estimated at $2.2 billion annually
02
More than 50% of COPD cases are undiagnosed or not recognized by health systems (diagnostic gap estimate in review literature)
03
A 2013 study estimated total economic burden of COPD in the US at $49 billion
04
A 2018 systematic review found that long-term home oxygen therapy improves survival in COPD patients with severe resting hypoxemia
05
Pulmonary rehabilitation reduces hospital admissions in COPD patients; a meta-analysis reported reductions of about 14% in hospitalization risk
06
In a large randomized trial, tiotropium (a LAMA) reduced COPD exacerbations compared with placebo (UPLIFT trial reported a 14% reduction in annual exacerbations versus placebo)
07
In the TORCH trial, fluticasone/salmeterol reduced the rate of COPD exacerbations versus placebo (reported rate ratio improvement)
08
Worldwide, 1 in 5 people with COPD have a diagnosis documented (undertreatment/diagnostic gap in COPD compared with prevalence estimates)
Interpretation
Treatment & Outcomes Interpretation
Across treatment and outcomes for COPD, evidence shows that targeted therapies can meaningfully improve results, including a 14% reduction in exacerbations with tiotropium and about a 14% reduction in hospitalization with pulmonary rehabilitation, while long-term home oxygen therapy improves survival in patients with severe resting hypoxemia.
02 · Category
Risk & Causes10 stats
01
A 10-year smoking cessation reduces the risk of COPD death by 50%
02
Alpha-1 antitrypsin deficiency is responsible for 1–3% of COPD cases
03
Up to 20% of people with COPD report that they have never smoked (proportion of COPD cases not attributed to smoking)
04
Among adults with COPD, 39% report difficulty with daily activities (e.g., walking, dressing) in a population survey
05
The proportion of COPD deaths attributed to smoking is high; smoking accounts for most COPD mortality in epidemiologic reviews
06
In a WHO report, household air pollution causes 3.8 million deaths per year globally and is a risk for COPD among other diseases
07
WHO estimates that outdoor air pollution contributes to about 4.2 million deaths per year globally, increasing COPD risk
08
WHO estimates that air pollution is a major risk factor for chronic respiratory diseases including COPD
09
COPD is associated with a higher risk of cardiovascular disease; co-morbidity prevalence is substantial (review literature)
10
In COPD, comorbid anxiety and depression are common; systematic review reports around 10–40% prevalence depending on measure
Interpretation
Risk & Causes Interpretation
Risk for emphysema and related COPD is strongly shaped by preventable exposures, with 10-year smoking cessation cutting the risk of COPD death by 50% and household air pollution driving 3.8 million deaths each year worldwide, even though up to 20% of COPD cases occur in people who report never smoking.
03 · Category
Diagnosis & Staging2 stats
01
In emphysema CT findings, low attenuation areas are used as a quantitative imaging marker of emphysema severity
02
In a lung function measure, emphysema severity can be quantified by diffusing capacity (DLCO) reduction reflecting impaired gas transfer
Interpretation
Diagnosis & Staging Interpretation
For diagnosis and staging, emphysema severity is increasingly tracked with CT low attenuation areas that serve as a quantitative imaging marker and with DLCO reduction, a lung function measure that reflects impaired gas transfer.
04 · Category
Market & Industry8 stats
01
In the Global Burden of Disease study, COPD ranked among the top 5 causes of death and disability worldwide in recent decades (ranked 3rd overall in 2019 for mortality and 7th for disability-adjusted life years)
02
The global COPD market was estimated at $XX in 2023 (pharmaceutical + related therapies) (industry estimate)
03
The number of COPD-focused clinical trials has increased in recent years according to ClinicalTrials.gov counts (annual updates)
04
The United States accounts for a large share of COPD medication sales due to high diagnosed prevalence (market-level fact from industry overview)
05
In 2021, there were 1.8 million hospital discharges with COPD as a diagnosis in the United States (HCUP statistics as reported in NCHS fastats)
06
COPD is among the top conditions addressed by respiratory biologics and targeted therapies development, with biologics emerging for inflammatory COPD phenotypes (pipeline overview in major review)
07
In 2010, COPD cost the United States $49.9 billion total, with direct medical costs of $29.9 billion and indirect costs of $20.0 billion (study)
08
FUNDING: Alpha-1 antitrypsin deficiency testing programs have expanded, with emphasis on identifying 1–3% of COPD caused by this deficiency (screening guidance)
Interpretation
Market & Industry Interpretation
Driven by COPD’s global burden and expanding R&D momentum, the COPD-focused clinical trials landscape is growing alongside a large and diagnosis-led market, with the United States alone seeing 1.8 million COPD hospital discharges in 2021.
05 · Category
Disease Burden4 stats
01
In 2019, COPD was the 3rd leading cause of death worldwide (including emphysema as a COPD phenotype) in the Global Burden of Disease results
02
In 2019, COPD ranked 7th for disability-adjusted life years (DALYs) worldwide, reflecting the total disease burden that includes emphysema as a COPD subtype, per Global Burden of Disease
03
In 2019, worldwide COPD prevalence was estimated at about 212 million people, which includes emphysema as a phenotype within COPD
04
In 2019, COPD caused 39.4 million disability-adjusted life years (DALYs) globally (Global Burden of Disease results for 2019)
Interpretation
Disease Burden Interpretation
In 2019, COPD ranked among the world’s top causes of death and disability with 212 million people living with it and 39.4 million DALYs lost globally, underscoring a major disease burden burden that also reflects emphysema within this COPD phenotype.
More related reading
06 · Category
Clinical Epidemiology9 stats
01
Starting from age 40, the prevalence of chronic bronchitis and emphysema increases with age; a large population-based analysis reported emphysema prevalence rising substantially across adult age bands (age-stratified prevalence study)
02
DLCO (diffusing capacity for carbon monoxide) is reduced in emphysema; in a cohort study of COPD, DLCO was among the strongest predictors of emphysema extent on CT (quantitative emphysema imaging study)
03
Mean CT emphysema extent severity categories based on low attenuation areas (LAA) correlate with lung function impairment; a meta-analysis reported moderate-to-strong correlations between LAA% and FEV1 and DLCO across studies
04
Emphysema severity by CT has been shown to associate with higher risk of exacerbations; a prospective study quantified that higher CT emphysema extent is linked to increased exacerbation frequency
05
In COPD cohorts, blood eosinophil count is associated with exacerbation risk; a large observational analysis reported that higher eosinophils were linked to increased responsiveness to inhaled corticosteroids (biomarker study including emphysema phenotype patients)
06
For emphysema, the presence of gas-trapping on expiratory CT (e.g., increased expiratory LAA) is common; a multicenter imaging study reported that gas-trapping measures co-occur with emphysema extent in the majority of participants
07
In a COPD population, about 15–20% of patients may have an emphysema-dominant phenotype (CT-based clustering study)
08
In newly diagnosed COPD, one large UK primary-care cohort reported that emphysema diagnoses are increasingly recognized over time due to better spirometry and imaging, with annual growth in coded emphysema rates
09
Pulmonary rehabilitation improves exercise capacity: a Cochrane review reported improvements in the 6-minute walk distance of roughly 46 meters on average for COPD patients after rehabilitation (including emphysema patients within COPD)
Interpretation
Clinical Epidemiology Interpretation
From a clinical epidemiology standpoint, the evidence shows that emphysema markers are increasingly common and clinically meaningful with age and imaging, with prevalence rising after age 40 and CT measures such as low attenuation areas and expiratory gas trapping tracking lung impairment and exacerbation risk.
07 · Category
Treatment Patterns9 stats
01
Inhaled bronchodilator therapy is associated with fewer COPD exacerbations; a network meta-analysis reported that LAMA reduced exacerbations vs placebo by a relative risk of about 0.77 (includes emphysema phenotype patients within COPD)
02
In a national audit, pulmonary rehabilitation uptake in COPD was low: one UK study reported only ~4% of eligible COPD patients received pulmonary rehabilitation (rehab uptake measure)
03
Annual influenza vaccination coverage among adults with COPD is reported at roughly 50–60% in US surveys; one NHIS-based analysis quantified coverage around 56% for COPD patients (seasonal flu vaccination)
04
Pneumococcal vaccination coverage among adults with COPD is reported around 40–50% in US surveys; a survey analysis quantified pneumococcal vaccination prevalence for COPD patients
05
Home oxygen therapy is used in severe hypoxemia; registry data in Europe show that a minority of COPD patients receive long-term oxygen, typically in the low single-digit percent range (severe hypoxemia subset)
06
Corticosteroid use in exacerbations: guideline-concordant systemic corticosteroids for COPD exacerbations typically involve 5 days of therapy; a guideline quantified evidence supporting short-course dosing
07
Smoking cessation pharmacotherapy use (e.g., nicotine replacement therapy or varenicline) among smokers with COPD is documented at low-to-moderate levels in surveys; a US analysis quantified cessation medication utilization among COPD smokers
08
Telehealth for COPD: a 2022 systematic review reported that telemonitoring reduced hospitalizations or emergency visits by a measurable relative percentage (includes COPD patients with emphysema)
09
Mortality after acute COPD exacerbation remains substantial: a large cohort study quantified 30-day all-cause mortality after COPD hospitalization at around 5–10% depending on severity and comorbidities
Interpretation
Treatment Patterns Interpretation
Across treatment patterns for emphysema and COPD, real world care often falls short of guideline targets, with only about 4% of eligible patients receiving pulmonary rehabilitation and influenza vaccination coverage staying around 50 to 60% despite evidence that therapies like LAMA can reduce exacerbations.
08 · Category
Economic Impact3 stats
01
Hospital readmissions are common after COPD exacerbations; a cohort study quantified 30-day readmission rates at around 15–25% for COPD admissions
02
Long-term oxygen therapy can increase costs; a systematic economic review quantified incremental costs per patient-year of oxygen therapy in COPD with severe resting hypoxemia
03
Pulmonary rehabilitation yields cost offsets by reducing utilization; an economic evaluation reported that pulmonary rehab is cost-effective for COPD in many settings, quantified by cost per QALY thresholds
Interpretation
Economic Impact Interpretation
From an economic impact perspective, COPD exacerbations frequently lead to 30-day hospital readmissions of about 15 to 25 percent, while long-term oxygen therapy adds incremental per patient-year costs and pulmonary rehabilitation can counterbalance these pressures by reducing healthcare utilization and improving cost-effectiveness.
09 · Category
Prevention & Risk7 stats
01
Household air pollution deaths are several million per year globally; an independent source quantified household air pollution mortality burden relevant to COPD risk
02
Outdoor air pollution exposure is associated with increased chronic respiratory mortality; a systematic review quantified the relative risk of COPD or chronic respiratory outcomes by PM2.5 exposure
03
Occupational exposures (dusts/chemicals) contribute to COPD risk; a meta-analysis quantified the relative risk for COPD associated with occupational exposure categories
04
Air pollution mitigation reduces COPD exacerbations; an observational study reported a measurable reduction in COPD exacerbations following PM2.5 declines
05
Vaccination reduces COPD-related lower respiratory infections; a meta-analysis quantified reductions in COPD exacerbations or pneumonia events after influenza vaccination
06
Pulmonary rehabilitation also supports smoking cessation indirectly; a trial measured cessation rates after combined rehab plus behavioral interventions and reported a measurable percent increase
07
Vitamin D supplementation trials: a meta-analysis reported a measurable effect on COPD exacerbation rates (relative risk) across randomized studies that include emphysema phenotype within COPD
Interpretation
Prevention & Risk Interpretation
Across prevention and risk, cutting harmful air pollution can save millions by reducing chronic and household exposure, while targeted measures like occupational risk control, vaccination, and even pulmonary rehabilitation support fewer COPD exacerbations and pneumonia events, reinforcing that prevention efforts can substantially lower emphysema risk and its downstream complications.
report visual · Breakdown
COPD (Including Emphysema) Burden: Diagnosis Gaps & Economic Costs
A large share of COPD cases go unrecognized, alongside substantial economic burden.
50%
More than 50% of COPD cases are undiagnosed or not recognized by health systems (diagnostic gap estimate in review liter
50%
A 10-year smoking cessation reduces the risk of COPD death by 50%
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Emphysema Statistics. Gitnux. https://gitnux.org/emphysema-statistics
MLA
Samuel Norberg. "Emphysema Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/emphysema-statistics.
Chicago
Samuel Norberg. 2026. "Emphysema Statistics." Gitnux. https://gitnux.org/emphysema-statistics.
Sources & references
60 datasets cited across this report · attribution is report-level
+45 additional datasets cited (not shown individually)